ANAB insider trading
NasdaqGS HealthcareANAPTYSBIO, INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About ANAPTYSBIO, INC
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Company website: www.anaptysbio.com
ANAB insider activity at a glance
FilingIQ has scored 453 insider transactions for ANAB since Jan 31, 2017. The most recent filing in our index is dated May 11, 2026.
Across the full history, 22 open-market purchases
and 137 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ANAB insider trades is 59.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ANAB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding ANAB
Frequently asked
- How many insider trades does FilingIQ track for ANAB?
- FilingIQ tracks 453 Form 4 insider transactions for ANAB (ANAPTYSBIO, INC), covering filings from Jan 31, 2017 onwards. 82 of those were filed in the last 90 days.
- Are ANAB insiders net buyers or net sellers?
- Across the full Form 4 history for ANAB, 22 transactions (5%) were open-market purchases and 137 (30%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ANAB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is ANAB in?
- ANAPTYSBIO, INC (ANAB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.58B.
Methodology & sources
Every ANAB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.